Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data basliginda one cikan gelisme: Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.